Cytalon 100 mg, 500 mg and 1000 mg Cytarabine Injection Vials

At a Glance

Generic Name: Cytarabine

Brand Name: Cytalon

Strength & Pack Size: 100 mg, 500 mg and 1000 mg single-use cytarabine vials

Dosage Form & Route: Lyophilised powder for IV, subcutaneous or intrathecal injection after reconstitution

Therapeutic Class: Antimetabolite chemotherapy (pyrimidine analogue)

Primary Indications: Acute leukaemias and related blood cancers, as per specialist protocols

Usual Use in Therapy: Induction, consolidation or intensification cycles in combination regimens

Prescription Status: Prescription-only cytotoxic medicine for hospital or specialist centre use

Storage: Store in the original carton below 25 °C, protected from light, and handle as cytotoxic

Product Description

Cytalon is a cytarabine-based injectable chemotherapy used in the treatment of acute leukaemias and related blood cancers under the supervision of experienced haematology teams. Each Cytalon vial contains cytarabine as a lyophilised powder that must be reconstituted with an appropriate diluent before use. Depending on the regimen, the reconstituted solution may be given intravenously, subcutaneously or, in specific protocols, by other specialist routes such as intrathecal administration. The availability of Cytalon 100 mg, 500 mg and 1000 mg vials allows clinicians to match the total cytarabine dose to body-surface-area–based calculations and specific cycle designs with precision.

Cytarabine has long been a cornerstone of acute myeloid leukaemia treatment and also features in regimens for other forms of leukaemia and certain haematologic conditions. Cytalon cytarabine vials can be incorporated into induction schedules aimed at rapidly reducing leukaemic blast counts and into consolidation or intensification phases designed to deepen and prolong remission. The exact role of Cytalon in an individual treatment plan depends on disease subtype, prior therapy, co-morbidities and local or international protocols followed by the treating centre. Cytalon cytarabine is not used as a self-administered medicine at home; all preparation and administration are carried out by trained healthcare professionals.

Generic Meds Mart supplies Cytalon 100 mg, 500 mg and 1000 mg cytarabine vials in original manufacturer cartons obtained from licensed oncology distributors. Each pack displays the brand name, strength, generic name, batch number, expiry date and storage conditions so hospital pharmacy teams can verify every vial before it is added to chemotherapy preparation workflows. Parcels are shipped in neutral outer packaging that does not mention leukaemia, cytarabine or chemotherapy, supporting patient privacy while still providing the traceability needed for safe cytotoxic handling. Our role is to support medicine access and logistics; all therapeutic decisions remain with your haematologists and oncologists.

Key Uses

Cytalon cytarabine vials are used in the management of various acute leukaemias and related blood cancers, most notably acute myeloid leukaemia. Cytarabine may also be part of regimens for acute lymphoblastic leukaemia, chronic myeloid leukaemia in blast crisis and certain meningeal or central nervous system involvements where intrathecal schedules are prescribed. Cytarabine is almost always used in combination with other chemotherapy agents and supportive measures rather than as a single agent.

The specific indication and schedule for Cytalon cytarabine depend on the precise leukaemia subtype, cytogenetic risk profile, age, organ function, infection status and previous treatments a patient has received. Some regimens use standard-dose cytarabine, while others employ high-dose cytarabine blocks as part of consolidation. Your haematology team will determine whether Cytalon cytarabine is suitable in your situation and, if so, at which stage of the treatment pathway it should be used and with which combination partners.

How Cytarabine Works in Chemotherapy

Cytarabine, the active ingredient in Cytalon, is an antimetabolite and pyrimidine analogue that interferes with DNA synthesis in rapidly dividing cells. Once administered, cytarabine is taken up into cells and converted into an active triphosphate form that competes with natural nucleotides during DNA replication. By being incorporated into growing DNA strands, cytarabine disrupts chain elongation and inhibits key enzymes, particularly DNA polymerase, that are essential for accurate DNA synthesis.

Leukaemic blasts and other rapidly dividing malignant cells rely heavily on continuous DNA replication, which makes them particularly vulnerable to cytarabine’s mechanism of action. As DNA synthesis becomes impaired, these abnormal cells accumulate damage and undergo cell death. Normal cells that divide quickly, such as bone marrow progenitors and gastrointestinal lining cells, can also be affected, which explains many of the side effects associated with cytarabine. The balance between anti-leukaemic efficacy and toxicity is carefully managed by experienced clinicians through dosing schedules, supportive care and close monitoring.

Dosage & Administration

Cytalon cytarabine dosage is determined entirely by the treating haematology team and often expressed in milligrams per square metre of body surface area. Regimens may involve continuous infusions over several days, intermittent infusions, subcutaneous injections or specialised intrathecal doses, depending on the protocol and disease setting. Cytalon 100 mg, 500 mg and 1000 mg vials provide flexibility for pharmacists and chemotherapy nurses to reconstitute the exact total cytarabine dose needed for each cycle or treatment block.

Cytalon vials must be reconstituted with the recommended diluent by trained staff using aseptic technique in a controlled preparation area, often a pharmacy clean room or chemotherapy mixing space. The reconstituted solution is then administered via a central or peripheral line, subcutaneous injection or other defined route, with patients monitored during and after treatment for side effects and infusion-related issues. Schedules typically include rest periods between cycles to allow bone marrow recovery and management of toxicities. Patients should never attempt to handle or inject Cytalon cytarabine themselves.

Precautions

Before starting Cytalon cytarabine, your medical team will review your blood counts, liver and kidney function, cardiac status, neurological history and any current infections. Cytarabine can cause profound bone marrow suppression, so a baseline full blood count and frequent monitoring during treatment are essential. Existing infections need to be treated and controlled, as cytarabine further suppresses the immune system and can increase the risk of serious or opportunistic infections.

Cytarabine may also affect liver and kidney function, so dose adjustments or special precautions might be necessary for patients with impaired organ function. In high-dose or intrathecal regimens, cytarabine has been associated with neurological side effects, so any previous neurological conditions will be taken into account when designing a treatment plan. Because cytarabine can be harmful to a developing baby, effective contraception is usually required during therapy and for a period afterwards, and cytarabine is generally avoided in pregnancy and breastfeeding unless there is a compelling reason and this is clearly documented by the treating team.

Cytarabine Side Effects

Common side effects

Common cytarabine side effects include bone marrow suppression leading to low white blood cell counts, low red cells and low platelets, which can manifest as increased susceptibility to infections, fatigue, pallor, easy bruising or bleeding. Gastrointestinal symptoms such as nausea, vomiting, diarrhoea, abdominal discomfort and mouth sores are also frequent, particularly at higher doses. Many patients experience hair thinning or hair loss, loss of appetite, mild fever, general weakness and injection-site irritation or phlebitis at the infusion site. These effects are often managed with anti-nausea medicines, mouth care protocols, growth factors, transfusions and supportive measures guided by the haematology team.

Serious side effects

Serious cytarabine adverse effects require urgent medical attention and may lead to dose adjustment or discontinuation. These include severe infections or sepsis in the setting of neutropenia, significant bleeding due to marked thrombocytopenia, severe mucositis, pronounced liver or kidney dysfunction, and rare but important neurological events such as cerebellar toxicity with unsteady gait, slurred speech or coordination difficulties. High-dose cytarabine or intrathecal cytarabine regimens need especially careful neurological monitoring. Any high fever, chills, confusion, unusual bruising, black or bloody stools, sudden difficulty walking, severe headache or new visual changes during Cytalon therapy should be reported immediately to the treating team or emergency services.

Storage

Unopened Cytalon 100 mg, 500 mg and 1000 mg vials should be stored below 25 degrees Celsius in their original cartons, protected from light and moisture, and handled in accordance with local cytotoxic medicine guidelines. Reconstituted cytarabine solutions have limited stability and must be used or discarded according to the product information and institutional policies, usually under the supervision of the hospital pharmacy or chemotherapy unit. Patients themselves are not expected to store, transport or dispose of reconstituted Cytalon vials; this is managed entirely by clinical staff using approved cytotoxic waste procedures.

Why Buy from Generic Meds Mart

Generic Meds Mart helps hospitals, clinics and patients access Cytalon cytarabine vials in regions where supply, cost or local distribution may otherwise limit choice. We work only with licensed oncology manufacturers and authorised distributors who follow Good Manufacturing Practice standards and maintain rigorous batch and expiry tracking. By supplying Cytalon 100 mg, 500 mg and 1000 mg vials in sealed, original cartons, we support hospital pharmacies in verifying product identity and strength before incorporation into chemotherapy protocols.

All Cytalon orders through Generic Meds Mart are processed in USD via secure online checkout, and shipments are packed in neutral outer cartons that do not mention leukaemia, cytarabine or chemotherapy. Where available, trackable delivery options allow haematology services to plan upcoming induction or consolidation cycles around confirmed delivery dates, helping to reduce the risk of treatment delays caused by supply issues. Our role is to support timely, discreet and verifiable access to the cytarabine strengths prescribed by your specialists; all decisions about when and how to use Cytalon remain strictly with your medical team.

Order Now

Before ordering Cytalon from Generic Meds Mart, you should already have a confirmed diagnosis of acute leukaemia or a related blood cancer and a clear written treatment plan from your haematologist that specifies cytarabine, the intended dose, the number of cycles and the route of administration. Your treating centre will determine whether Cytalon is a suitable cytarabine brand for your regimen and will calculate how many 100 mg, 500 mg and 1000 mg vials are required for each cycle and for the full planned course.

You should not attempt to choose cytarabine doses, alter vial strengths or modify your schedule on your own. If you experience new or worsening symptoms such as high fever, uncontrolled bleeding, sudden confusion, difficulty walking, severe abdominal pain, chest pain or shortness of breath during cytarabine-based treatment, seek urgent medical attention rather than adjusting or stopping therapy yourself. Generic Meds Mart exists to help ensure that the Cytalon cytarabine your specialists have selected is available in the right strengths at the right time, while the complex medical management of your cancer remains in the hands of your haematology team.

FAQ about Cytalon (Cytarabine)

Q1: What types of cancer is Cytalon used to treat?

Cytalon contains cytarabine, an antimetabolite chemotherapy used mainly in the treatment of acute leukaemias and some related blood cancers. Depending on the protocol, cytarabine can be part of induction, consolidation or intensification regimens for acute myeloid leukaemia and other leukaemia subtypes, always under specialist supervision.

Q2: How is Cytalon different from oral chemotherapy?

Cytalon cytarabine is supplied as vials of lyophilised powder that must be reconstituted and given by injection or infusion, not taken by mouth. This allows precise control over dose and route, including intravenous, subcutaneous and, in selected cases, intrathecal administration. Because it is a potent cytotoxic medicine, Cytalon is prepared and administered only in hospitals or specialist centres, unlike some oral chemotherapy tablets that patients may take at home according to instructions.

Q3: Will I need to stay in hospital while receiving Cytalon?

Whether treatment with Cytalon cytarabine requires inpatient admission or can be given in a day-case setting depends on the specific regimen, your overall health, blood counts and the intensity of monitoring required. Some cytarabine schedules are delivered during hospital stays, while others may be administered in day-care units with regular visits. Your haematology team will explain the planned setting for each phase of your cytarabine-based therapy.

Q4: Can Cytalon be used again if my leukaemia relapses?

In some situations cytarabine can be used in more than one phase of therapy, for example in both initial induction and later relapse regimens, but this depends on your previous exposure, cumulative dose, response and side-effect profile. Your haematologist will consider prior treatments, remission duration and current disease features before deciding whether another cytarabine-containing regimen, including Cytalon, is appropriate in the relapse setting.

Q5: What can I do to reduce infection risks while on Cytalon?

Because cytarabine lowers white blood cell counts, infection prevention is very important during Cytalon treatment. Your team may recommend measures such as careful hand hygiene, avoiding crowds and people with obvious infections, following any neutropenic diet advice given locally, and promptly reporting fevers or signs of infection. In some regimens, prophylactic antibiotics, antivirals or antifungals may be used. Your haematology unit will provide specific written guidance tailored to your situation.

Zavedos Idarubicin – 5 mg Injection Vial

At a Glance

Generic Name: Idarubicin Hydrochloride

Brand Name: Zavedos 5 mg

Strength & Pack Size: 5 mg idarubicin per vial, 1 single-use vial

Dosage Form & Route: Lyophilised powder for solution for IV injection or infusion

Therapeutic Class: Anthracycline cytotoxic chemotherapy

Primary Indications: Induction and consolidation regimens for acute myeloid leukaemia (AML) and selected acute leukaemia protocols, according to local label

Typical Use in Therapy: Combined with other cytotoxics (such as cytarabine) in intensive hospital-based regimens under haematology supervision

Mode of Action: Intercalates DNA, inhibits topoisomerase II and generates free radicals, disrupting DNA replication and repair

Key Benefits: Established anthracycline backbone in many AML protocols when used with appropriate supportive care

Precautions: Risk of myelosuppression, cardiotoxicity, mucositis and organ toxicity; requires close monitoring in a specialist centre

Storage: Store as directed on the carton, usually below 25 °C, protected from light in the original outer pack

Product Description

Zavedos 5 mg contains idarubicin hydrochloride, an anthracycline cytotoxic medicine used predominantly in the treatment of acute myeloid leukaemia (AML) and selected acute leukaemia protocols. Each single-use vial provides 5 mg of idarubicin as a lyophilised powder that must be reconstituted with a suitable diluent before intravenous administration. Zavedos 5 mg idarubicin injection is restricted to hospital and specialist haematology settings, where experienced teams manage complex induction and consolidation chemotherapy with full access to supportive care.

In many treatment protocols, Zavedos 5 mg idarubicin injection is combined with cytarabine and other agents to achieve remission in AML. It may also appear in variations of acute leukaemia regimens depending on national guidelines, trial data and institutional practice. Because idarubicin is a potent anthracycline with the potential for both short-term and long-term toxicity, its use is carefully weighed against disease severity, patient fitness, prior anthracycline exposure and cardiac status. This is not a medicine for outpatient self-administration; every step from reconstitution to infusion is handled by trained oncology or haematology staff.

Generic Meds Mart supplies Zavedos 5 mg idarubicin injection only in original manufacturer packaging obtained from licensed distributors. Each vial is sealed and carries a clearly printed batch number and expiry date so hospital pharmacies can document traceability. Outer shipping cartons are neutral, without visible references to leukaemia, anthracyclines or idarubicin, helping protect privacy during international delivery. Pricing is shown in USD to support planning for multi-cycle chemotherapy that may involve several vials across induction and consolidation phases.

Key Uses

In clinical practice, Zavedos 5 mg idarubicin injection is used as part of combination chemotherapy for acute myeloid leukaemia and, in some settings, other acute leukaemias where idarubicin is incorporated into validated protocols. Typical uses include induction regimens aimed at achieving complete remission and consolidation courses designed to deepen and maintain the response.

The exact protocol, number of cycles and combination partners differ by region and institutional guidelines. Some centres reserve idarubicin for particular risk groups or disease subtypes, while others use it within standard AML induction regimens. Decisions about whether to use idarubicin rather than other anthracyclines such as daunorubicin are made by haematologists based on evidence, local practice, patient comorbidities and cumulative anthracycline exposure. Zavedos 5 mg is one component of a broader plan that may include further chemotherapy, stem cell transplantation or maintenance strategies.

How Idarubicin Works in Chemotherapy

Idarubicin, the active ingredient in Zavedos 5 mg injection, is an anthracycline antineoplastic agent. It exerts its cytotoxic effect through multiple mechanisms, including DNA intercalation, inhibition of topoisomerase II and generation of free radicals that damage cellular components. By intercalating between DNA base pairs, idarubicin disrupts DNA structure and interferes with replication and transcription. Topoisomerase II inhibition prevents the proper unwinding and re-ligation of DNA strands, further impairing replication and repair.

These actions are particularly harmful to rapidly dividing cells, such as leukaemic blasts in the bone marrow. When Zavedos 5 mg idarubicin injection is combined with other agents like cytarabine, the effects on DNA synthesis and repair can be synergistic, enhancing the likelihood of inducing remission. However, this same potency underlies the risk of damage to normal rapidly dividing cells, including bone marrow progenitors, gastrointestinal mucosa and hair follicles, as well as potential cumulative injury to cardiac tissue over time.

Dosage & Administration

Zavedos 5 mg idarubicin injection must only be prescribed and administered by haematologists or oncologists experienced in intensive leukaemia chemotherapy. Each vial contains 5 mg of idarubicin powder for reconstitution. The dose is typically calculated on the basis of body surface area (mg/m²) and administered intravenously over a defined time interval, often on specific days of a chemotherapy cycle alongside other agents.

Reconstitution and dilution are performed under aseptic, cytotoxic handling conditions in a pharmacy or chemotherapy preparation unit. Nurses trained in cytotoxic administration then deliver the dose via a central or peripheral venous line, monitoring for extravasation and infusion reactions. Zavedos 5 mg idarubicin injection is never given by the patient at home and must not be administered intramuscularly or subcutaneously. Frequent blood counts, biochemistry tests and clinical assessments guide decisions about subsequent doses, cycle timing and supportive interventions such as transfusions or growth factor support.

Precautions

Before initiating Zavedos 5 mg idarubicin injection, the treatment team reviews cardiac function, prior anthracycline exposure, liver and kidney function, performance status and infection risk. Anthracyclines are associated with dose-dependent cardiomyopathy, so baseline assessment of left ventricular ejection fraction is standard, with follow-up imaging where indicated. Patients with significant pre-existing cardiac disease may require alternative regimens or careful modification of anthracycline dosing.

Myelosuppression is expected and often profound, so patients receiving Zavedos 5 mg must be treated in centres capable of delivering transfusions, broad-spectrum antibiotics, antifungals, growth factors and intensive supportive care. Adequate liver and kidney function are important to handle metabolism and excretion of idarubicin and its metabolites. Fertility counselling is usually offered before treatment starts, and effective contraception is advised during therapy and for a period afterwards, as idarubicin is contraindicated in pregnancy and may harm an unborn child.

Idarubicin Side Effects

Common side effects

Common idarubicin side effects in patients receiving Zavedos 5 mg injection include myelosuppression with neutropenia, thrombocytopenia and anaemia; increased susceptibility to infections; hair loss; nausea and vomiting; mucositis affecting the mouth and gastrointestinal tract; diarrhoea or constipation; fatigue; and temporary changes in liver function tests. The urine or tears may take on a reddish colour for a short period due to the anthracycline pigment, which is usually benign but can be alarming if not anticipated.

With experienced supportive care, many of these common idarubicin side effects can be managed. Centres that use Zavedos 5 mg routinely will provide antiemetic regimens, oral care protocols, nutritional support and transfusion strategies. Patients and families are counselled on signs of infection, bleeding and dehydration so they can seek help promptly.

Serious side effects

Serious idarubicin adverse effects require immediate medical attention. These may include severe or prolonged bone marrow suppression leading to septic shock or major haemorrhage; clinically significant cardiotoxicity with heart failure symptoms; severe mucositis preventing oral intake; acute liver or kidney injury; and severe extravasation injury if the drug leaks from the vein into surrounding tissue. Anthracyclines have also been associated with secondary malignancies after long-term follow-up in some patients, though this risk must be weighed against the immediate need to treat life-threatening leukaemia.

Patients are instructed to contact the treatment centre or emergency services urgently if they develop high fever, chills, shortness of breath, chest pain, sudden weight gain with swelling, uncontrolled bleeding, severe mouth or throat pain, confusion, markedly reduced urine output or any other alarming symptom during or after a cycle containing Zavedos 5 mg idarubicin injection. The team may need to adjust further therapy, intensify supportive care or consider alternative regimens.

Storage

Zavedos 5 mg idarubicin injection vials should be stored exactly as described on the product carton and in the package leaflet, usually below 25 °C, protected from light in the original outer carton. Vials must be kept out of the sight and reach of children. Reconstituted solutions have a limited stability window and must be used or discarded according to cytotoxic preparation guidelines. Unused solution, vials, syringes and infusion lines that have come into contact with idarubicin should be disposed of as cytotoxic waste, following local regulations and institutional policies.

Why Buy from Generic Meds Mart

Generic Meds Mart is focused on structured access to key oncology medicines such as Zavedos 5 mg idarubicin injection. We partner only with licensed manufacturers and authorised distributors that comply with Good Manufacturing Practice and maintain full batch traceability. Each vial of Zavedos 5 mg supplied by Generic Meds Mart is delivered in sealed original packaging so hospital pharmacies can confirm brand, strength, batch number and expiry before release to the chemotherapy unit.

By listing Zavedos 5 mg in USD, we help treatment centres and patients plan for the cost of multi-cycle AML regimens that may require multiple vials. Neutral outer cartons protect confidentiality during international shipping, while tracking (where available) supports coordination between delivery and scheduled chemotherapy cycles. Our role is limited to supply and logistics; all decisions about when and how to use idarubicin remain strictly with the treating haematology or oncology team.

Order Now

Zavedos 5 mg idarubicin injection is a potent anthracycline cytotoxic medicine reserved for specialist use in acute leukaemia chemotherapy. It must never be ordered for unsupervised or home administration. Before arranging supply through Generic Meds Mart, the treating team should confirm the indication, planned protocol, number of cycles, required idarubicin dose per cycle, cumulative anthracycline limits and supportive care resources.

Once that plan is documented, a designated purchaser or pharmacist can calculate the number of Zavedos 5 mg vials needed for the initial induction and consolidation phases. They can then select the appropriate quantity on Generic Meds Mart, add it to the cart and complete secure checkout in USD. Vials will be shipped in discreet outer packaging with full original labelling inside. Patients and caregivers should direct all clinical questions about idarubicin, side effects or dose modifications to their haematology team and must not attempt to handle or administer Zavedos 5 mg themselves.

FAQ about Zavedos (Idarubicin)

Q1: What is Zavedos 5 mg used for?
Zavedos 5 mg contains idarubicin, an anthracycline cytotoxic agent used primarily in induction and consolidation protocols for acute myeloid leukaemia (AML) and selected acute leukaemia regimens, according to local product information and specialist guidelines.

Q2: Can Zavedos 5 mg be given outside hospital?
No. Zavedos 5 mg idarubicin injection is prepared and administered only in hospital or specialist centres with facilities for intensive chemotherapy, cytotoxic handling and full supportive care. It is not suitable for outpatient self-administration.

Q3: How is Zavedos 5 mg administered?
Each vial of Zavedos 5 mg idarubicin injection is reconstituted and further diluted as required, then given intravenously by trained staff. Doses are calculated in mg/m² as part of a larger chemotherapy regimen. Administration routes, infusion times and schedules must follow the official product information and institutional protocols.

Q4: Why is heart monitoring important with idarubicin?
Idarubicin, like other anthracyclines, can cause cumulative cardiotoxicity and may lead to reduced heart function or heart failure. Baseline and follow-up heart assessments, such as echocardiograms, help specialists track cardiac function and adjust anthracycline exposure to reduce risk while still treating the leukaemia effectively.

Q5: What should patients watch for during treatment with Zavedos 5 mg?
Patients and caregivers should pay close attention to fever, chills, signs of infection, unusual bleeding or bruising, severe mouth sores, persistent vomiting or diarrhoea, chest pain, shortness of breath, sudden swelling, profound fatigue or reduced urine output. Any such symptoms should prompt immediate contact with the treatment centre or emergency services, as they may indicate serious idarubicin-related complications.

Cytosar Cytarabine – 100 mg Injection (1 pack / 5 ampoules)

At a Glance

Generic Name: Cytarabine

Brand Name: Cytosar

Strength & Pack Size: 100 mg per ampoule, 1 pack / 5 ampoules

Dosage Form & Route: Solution for IV, subcutaneous or intrathecal use in hospital settings

Therapeutic Class: Antimetabolite antineoplastic (pyrimidine analogue)

Primary Indications: Acute myeloid leukaemia (AML), acute lymphoblastic leukaemia (ALL), blast crisis of chronic myeloid leukaemia and meningeal leukaemia

Typical Use in Therapy: Backbone component of induction, consolidation and maintenance chemotherapy regimens under specialist protocols

Mode of Action: S-phase–active DNA synthesis inhibitor via conversion to cytarabine triphosphate

Key Benefits: Long-established role in acute leukaemia protocols worldwide, including systemic and intrathecal schedules

Precautions: Profound myelosuppression, neurotoxicity, gastrointestinal toxicity and infection risk require close monitoring

Storage: Store in original packaging at the temperature specified in the leaflet; hospital pharmacy manages handling and disposal

Product Description

Cytosar 100 mg contains cytarabine, a pyrimidine analogue antimetabolite that has been a central part of acute leukaemia treatment for many years. This presentation provides five ampoules, each containing 100 mg cytarabine in solution for injection. Cytosar is intended exclusively for use in hospital or specialist clinic settings, where trained haematology–oncology teams prepare and administer it as part of structured chemotherapy protocols.

In clinical practice, cytarabine is used both as systemic therapy and, at appropriate doses and concentrations, as intrathecal prophylaxis or treatment for meningeal leukaemia. It is rarely, if ever, given as a stand-alone single agent; instead, Cytosar cytarabine is integrated into combination regimens with other cytotoxic drugs and supportive medicines designed to induce remission, consolidate response and reduce the risk of relapse. The 100 mg ampoule strength is convenient for flexible dosing calculations based on body surface area and protocol requirements.

Generic Meds Mart supplies Cytosar 100 mg cytarabine injection in original manufacturer cartons with clear cytotoxic labelling, batch numbers and expiry dates. We focus on structured access and logistics, working only with licensed distributors and manufacturers. All clinical decisions about whether cytarabine is appropriate, which doses to use, how to combine it with other medicines and how to manage side effects remain firmly with your treating haematology–oncology team.

Key Uses

Within locally approved indications and up-to-date guidelines, Cytosar 100 mg cytarabine injection is typically used for:

• Induction therapy in acute myeloid leukaemia (AML) when combined with anthracyclines or other agents.
• Consolidation and, in some protocols, maintenance or post-remission therapy for AML.
• Selected regimens in acute lymphoblastic leukaemia (ALL) and in blast crisis of chronic myeloid leukaemia (CML) where cytarabine-containing combinations are appropriate.
• Intrathecal treatment or prophylaxis of meningeal leukaemia as part of central nervous system–directed therapy.

The exact indication, schedule and use of Cytosar are defined by specialist treatment protocols that take into account age, comorbidities, previous therapy, cytogenetic and molecular risk, and local standards of care.

How Cytarabine Works in Chemotherapy

Cytarabine, the active ingredient in Cytosar 100 mg injection, is a cytosine arabinoside–based antimetabolite that interferes with DNA synthesis. After administration, cytarabine is taken up by cells and converted intracellularly to its active metabolite, cytarabine triphosphate (Ara-CTP). Ara-CTP competes with the natural nucleoside deoxycytidine triphosphate for incorporation into DNA, leading to faulty DNA chains and inhibition of DNA polymerase.

Because these actions are most pronounced in the S-phase of the cell cycle, cytarabine preferentially affects rapidly dividing cells, including leukaemic blasts. By inhibiting DNA replication and repair mechanisms in these malignant cells, Cytosar can contribute to their death during intensive chemotherapy regimens. This S-phase specificity and the ability to achieve high concentrations in the central nervous system with certain dosing schedules underpin cytarabine’s role in both systemic and intrathecal leukaemia therapy.

Dosage & Administration

All dosing and administration of Cytosar 100 mg cytarabine injection must be determined by experienced haematologists or oncologists following established protocols and product information. Cytarabine regimens vary widely and may include low-dose, intermediate-dose or high-dose schedules, delivered as intermittent IV boluses, short infusions, continuous infusions or subcutaneous injections. In selected cases and at appropriate concentrations, cytarabine is administered intrathecally as part of CNS-directed leukaemia therapy.

Dose and schedule are typically based on body surface area, disease type, treatment phase, organ function and prior therapies. Intensive cytarabine therapy requires hospital admission, specialist nursing care and access to transfusion support, infection management and close laboratory monitoring. Cytosar must never be self-administered and should not be handled by patients or caregivers at home outside of a clear and approved hospital-directed plan.

Precautions

Cytarabine is associated with profound bone marrow suppression, which can lead to severe neutropenia, thrombocytopenia and anaemia. As a result, patients receiving Cytosar 100 mg injection require frequent full blood counts and, where necessary, red cell and platelet transfusions, growth factor support and infection prophylaxis or treatment. Fever, mucositis, unexplained bruising or bleeding and signs of infection require urgent clinical assessment.

At higher doses, cytarabine can cause specific neurotoxicities, including cerebellar dysfunction with ataxia, dysarthria and nystagmus, particularly in older patients or those with renal impairment. Eye toxicity such as conjunctivitis and keratitis may occur, and prophylactic steroid eye drops are often recommended during high-dose cytarabine therapy according to local protocols. Cytarabine can also contribute to gastrointestinal toxicity (nausea, vomiting, diarrhoea, abdominal pain), hepatic enzyme elevations and, rarely, pulmonary toxicity or myocardial impairment.

Cytarabine is teratogenic and should be avoided in pregnancy unless potential benefit clearly outweighs risk and no safer alternatives exist. Effective contraception is recommended for patients and partners during and after treatment as advised by the specialist team. Breastfeeding is usually not recommended during cytarabine therapy. All concomitant medicines, including other chemotherapy, antibiotics, antifungals and antivirals, should be reviewed for interactions and overlapping toxicities.

Cytarabine Side Effects

Common side effects

Common cytarabine side effects with Cytosar 100 mg injection, particularly at standard doses, include bone marrow suppression with low white blood cells, red cells and platelets, fatigue, fever, mucositis, nausea, vomiting, decreased appetite, mild liver enzyme elevations, hair thinning or loss, injection-site irritation and transient rash. Many patients also experience general malaise and increased susceptibility to infections during nadir periods.

These common cytarabine side effects are typically managed with planned supportive care: antiemetics, mouth care protocols, transfusions, growth factors where appropriate, infection surveillance and prompt antibiotic therapy. Regular monitoring allows clinicians to distinguish manageable toxicity from early warning signs of more serious complications that may require dose adjustment or treatment interruption.

Serious side effects

Serious cytarabine adverse effects require urgent specialist attention. These can include severe or prolonged bone marrow suppression with sepsis or life-threatening infections, significant bleeding, high-grade mucositis, severe diarrhoea, signs of cerebellar toxicity (unsteady gait, slurred speech, difficulty with coordination), seizures, confusion, severe visual disturbance, acute respiratory distress, chest pain or signs of myocardial injury.

If any of these warning signs occur during a Cytosar-containing regimen, patients should seek immediate medical care and inform their treating team that they are receiving cytarabine. The haematology–oncology team may need to stop or modify treatment, arrange urgent investigations, escalate supportive therapy and manage complications in a high-dependency or intensive care setting where necessary.

Storage

Cytosar 100 mg cytarabine injection should be stored in its original carton at the temperature recommended in the product leaflet, protected from light and extremes of heat. In practice, storage and handling are usually managed entirely by hospital or specialist clinic pharmacies, which also ensure correct preparation, dilution and disposal in line with cytotoxic safety regulations. Ampoules should not be used after the expiry date on the pack, and any unused solution or materials in contact with cytarabine must be discarded according to local hazardous waste procedures.

Why Buy from Generic Meds Mart

Generic Meds Mart is dedicated to structured access for essential oncology and haematology medicines such as Cytosar 100 mg cytarabine injection. We work only with licensed manufacturers and authorised distributors, and we supply Cytosar in original cartons with clearly visible batch numbers and expiry dates so that hospital and clinic pharmacies can verify authenticity and traceability.

Pricing is shown in USD to assist hospitals, clinics and patients in budgeting for multi-cycle acute leukaemia treatment plans. We ship using neutral outer packaging with no reference to cancer, chemotherapy or leukaemia on the outside, and we offer trackable shipping options where regulations allow. Our role is limited to supply and logistics; we do not make medical decisions and do not advise on individual cytarabine dosing, regimen selection or suitability.

Order Now

Cytosar 100 mg cytarabine injection is a potent antineoplastic medicine that must only be used within carefully controlled hospital protocols. Before arranging supply through Generic Meds Mart, ensure that a haematology–oncology team has confirmed the diagnosis, defined a cytarabine-containing regimen, reviewed organ function and discussed risks and benefits in detail with the patient or caregivers.

Once a clear plan is in place, the treating centre or authorised purchaser can calculate how many packs of Cytosar 100 mg (1 pack / 5 amps) are needed for induction, consolidation or CNS-directed phases. The required quantities can then be ordered on Generic Meds Mart, added to the cart and checked out securely in USD. Medicines will be shipped in discreet packaging, but all aspects of administration, monitoring, side-effect management and decisions about dose changes or discontinuation must remain with the specialist team, not the patient.

FAQ about Cytosar (Cytarabine)

Q1: What is Cytosar used for?
Cytosar contains cytarabine, an antimetabolite chemotherapy medicine primarily used in combination regimens for acute myeloid leukaemia (AML), certain acute lymphoblastic leukaemia (ALL) protocols, blast crisis of chronic myeloid leukaemia and intrathecal treatment or prophylaxis of meningeal leukaemia, according to local guidelines.

Q2: Is Cytosar given as an injection or infusion?
Cytosar 100 mg cytarabine injection is supplied as a solution in ampoules that can be given as IV bolus, short infusion, continuous infusion, subcutaneous injection or intrathecal dose, depending on the protocol. The exact method is determined by the treating haematology–oncology team and is always carried out in a controlled medical setting.

Q3: Why does Cytosar require so much monitoring?
Cytarabine can cause profound bone marrow suppression, serious infections and organ toxicities, especially at higher doses. Frequent blood tests, neurological checks, eye assessments, infection surveillance and supportive care measures are needed to keep treatment as safe and effective as possible. Monitoring requirements are part of the reason Cytosar is reserved for specialised centres.

Q4: Can Cytosar be taken at home?
Cytosar 100 mg cytarabine injection is not a self-administered medicine and is not intended for routine home use by patients or caregivers. Even when parts of a regimen are delivered in an outpatient setting, preparation and administration are handled by trained professionals with access to emergency support. Any questions about where treatment will take place should be discussed with the treating team.

Q5: Does Cytosar cure leukaemia?
Cytarabine is a key component of many curative-intent protocols for acute leukaemia, but it is rarely the only drug used, and long-term outcomes depend on multiple factors, including leukaemia subtype, risk profile, response to therapy and any subsequent transplantation or maintenance strategies. Only your haematology–oncology team can explain the realistic goals of a Cytosar-containing regimen in your specific situation.

Azadine 100 mg Azacitidine Injection (1 vial)

At a Glance

Generic Name: Azacitidine

Brand Name: Azadine 100 mg

Strength & Pack Size: 100 mg azacitidine, 1 vial of lyophilised powder for injection

Dosage Form & Route: Powder for suspension or solution, for subcutaneous (SC) or intravenous (IV) administration after reconstitution

Therapeutic Class: Hypomethylating antineoplastic agent

Primary Indications: Myelodysplastic syndromes (MDS) and selected acute myeloid leukemia (AML) cases, as per local label

Typical Patient Setting: Adults treated in specialist haematology–oncology centres with access to intensive monitoring

Mode of Action: Inhibits DNA methyltransferase, leading to hypomethylation and direct cytotoxic effects on abnormal marrow cells

Key Benefits: Proven improvement in blood counts and survival in higher-risk MDS and certain AML populations when used appropriately

Precautions: Requires close monitoring of blood counts, organ function and injection site reactions; hospital infrastructure recommended

Storage: Store in the original carton at the temperature stated in the leaflet; protect from light and follow reconstitution stability guidance

Product Description

Azadine 100 mg azacitidine injection is a hypomethylating agent used in the treatment of myelodysplastic syndromes (MDS) and in selected acute myeloid leukemia (AML) settings according to local prescribing information and specialist guidelines. Azacitidine targets abnormal bone marrow cells by interfering with DNA methylation and exerting direct cytotoxic effects, helping to restore more normal blood cell production over time.

Each vial of Azadine 100 mg contains 100 mg of azacitidine as a sterile lyophilised powder that must be reconstituted with an appropriate diluent before administration. Depending on local protocols, the reconstituted suspension or solution is given either subcutaneously or intravenously in repeated treatment cycles. Because of the risks of myelosuppression, infection and other serious side effects, Azadine 100 mg injection is used under the supervision of experienced haematologists and oncologists in facilities that can provide supportive care and regular monitoring.

When you buy Azadine 100 mg online from Generic Meds Mart, you receive original manufacturer vials in sealed cartons with clearly visible batch numbers and expiry dates. Products are sourced only from licensed distributors experienced in oncology and haematology supply chains. Outer shipping boxes are neutral, without visible references to MDS, AML or chemotherapy, to protect patient privacy, while maintaining complete traceability for pharmacies and clinics. Our mission is to support access and logistics; all treatment decisions remain with your specialist team.

Key Uses

Azadine 100 mg azacitidine injection is used in adults for myelodysplastic syndromes (MDS) and certain acute myeloid leukemia (AML) presentations, as defined in regional labels and guidelines. Typical indications include:

• Myelodysplastic syndromes (MDS), including subtypes with excess blasts, where disease-modifying hypomethylating therapy is indicated.
• Selected cases of AML, particularly those evolving from MDS or with lower blast percentages, where azacitidine-based regimens are supported by local protocols.

The choice to use Azadine 100 mg is individualized and considers patient age, performance status, cytogenetic and molecular risk, comorbidities and eligibility for alternative options such as intensive chemotherapy or stem cell transplantation. Azacitidine injection is often chosen for higher-risk MDS or for patients in whom traditional intensive regimens would be inappropriate or poorly tolerated.

How Azacitidine Works in Chemotherapy

Azacitidine, the active ingredient in Azadine 100 mg, is a cytidine analogue that exerts its antineoplastic effects through dual mechanisms. At lower concentrations, azacitidine incorporates into RNA and DNA and inhibits DNA methyltransferase, leading to hypomethylation of DNA. This hypomethylation can reactivate silenced tumour suppressor genes and modify abnormal gene expression patterns in dysplastic bone marrow cells.

At higher concentrations, azacitidine has direct cytotoxic effects on rapidly dividing cells, leading to cell death. In the context of myelodysplastic syndromes and certain AML subtypes, these mechanisms help reduce the burden of abnormal progenitor cells and support recovery of more normal haematopoiesis over repeated treatment cycles. Response to azacitidine therapy builds gradually, so clinicians often continue treatment for multiple cycles before judging benefit, provided tolerance and safety profiles remain acceptable.

Dosage & Administration

The dosing of Azadine 100 mg azacitidine injection is defined by body surface area and local prescribing information. A commonly used regimen in MDS involves administration of azacitidine for a set number of days in a 28-day cycle, given either subcutaneously or intravenously. Regimens, exact dose in mg/m², route and number of treatment cycles may vary based on label, institutional practice and individual patient factors.

Azadine vials must be reconstituted with the recommended diluent, using aseptic technique, and the resulting suspension or solution is administered within defined stability periods. Administration is performed only by trained healthcare professionals. Blood counts, kidney and liver function, as well as clinical status, are closely monitored before and during each cycle. Dose delays, reductions or interruptions may be necessary in response to myelosuppression, infections or other toxicities. Patients should never attempt to reconstitute or administer azacitidine themselves.

Precautions

Before starting Azadine 100 mg, your haematology team will review your full medical history, including prior treatments, performance status, infection risk, kidney and liver function and concurrent medications. Baseline blood counts and biochemistry help guide eligibility and dosing. Because azacitidine can cause profound myelosuppression, the risk of infections and bleeding must be considered, and prophylactic or early-intervention strategies may be used where appropriate.

Patients may be counselled about the potential need for blood or platelet transfusions, antimicrobial prophylaxis, hospital admission during infections and frequent laboratory monitoring. Azacitidine injection is not suitable for all patients; those with severe organ dysfunction or uncontrolled infections may require stabilisation before treatment or alternative approaches. Women and men of childbearing potential are usually advised to use effective contraception during treatment and for a period afterwards, as azacitidine can harm a developing baby. Breastfeeding is generally not recommended during therapy.

Azacitidine Side Effects

Common side effects

Common azacitidine side effects during Azadine 100 mg therapy include nausea, vomiting, diarrhoea or constipation, loss of appetite, fatigue, weakness, injection site reactions (for subcutaneous administration), mild rash, headache and low-grade fever. Haematologic side effects are very frequent and may involve reduced white cells, red cells and platelets, leading to higher risk of infections, anaemia and bruising or bleeding.

Many of these reactions can be managed with supportive medicines such as antiemetics, analgesics, topical measures for injection sites, growth factors in selected cases, transfusions and dose adjustments or cycle delays. Patients are encouraged to report any new or worsening symptoms promptly so that the medical team can intervene early and adjust treatment if needed.

Serious side effects

Serious azacitidine adverse effects require urgent medical attention and may include severe neutropenia with life-threatening infections, sepsis, severe thrombocytopenia with major bleeding, serious allergic reactions, pronounced liver or kidney injury, severe gastrointestinal events and rare but significant cardiac complications.

Warning signs to watch for include high or persistent fever, chills, severe sore throat, shortness of breath, chest pain, confusion, uncontrolled bleeding or bruising, black stools, vomiting blood, severe abdominal pain, markedly reduced urine output, yellowing of the skin or eyes or sudden swelling. If any of these occur during treatment with Azadine 100 mg azacitidine injection, emergency medical help should be sought immediately and healthcare professionals informed that you are receiving a hypomethylating agent.

Storage

Azadine 100 mg vials should be stored in their original cartons at the temperature specified in the product leaflet, protected from light and kept out of reach of children. They should not be frozen. After reconstitution, the azacitidine suspension or solution has a limited stability window and specific storage conditions, which must be followed closely by the pharmacy and infusion or day-care unit. Unused reconstituted product and materials used for preparation and administration must be disposed of as cytotoxic waste according to local regulations.

Why Buy from Generic Meds Mart

Generic Meds Mart is focused on improving access to essential haematology–oncology therapies such as Azadine 100 mg azacitidine injection, particularly in regions where availability and pricing can be barriers. We collaborate only with licensed manufacturers and authorised distributors who follow recognised quality and safety standards and provide full batch traceability. By supplying Azadine 100 mg in sealed original packaging, we support hospital pharmacies and clinics in verifying product authenticity and integrity.

Orders are processed in USD using secure online payment systems. Shipments are prepared in neutral outer packaging without visible oncology references, with the option for tracked delivery where available. This helps centres plan treatment cycles and ensure that azacitidine vials arrive in time for scheduled therapy. Our role is purely logistical; decisions about whether azacitidine is suitable, how many cycles to give and how to manage side effects are entirely the responsibility of the treating haematology–oncology team.

Order Now

Before arranging to buy Azadine 100 mg azacitidine injection online from Generic Meds Mart, you should have a confirmed diagnosis of myelodysplastic syndrome or AML where azacitidine is recommended, and a clear treatment plan from your specialist detailing dose, route, schedule and monitoring requirements. Your team will explain how azacitidine therapy fits into your overall care, expected benefits, potential risks and the importance of regular follow-up.

Once this plan is in place, your clinic or you, in agreement with your doctors, can determine how many Azadine 100 mg vials are needed per cycle and for the planned number of cycles. After you select the required quantity, you can complete secure checkout in USD. You should never start, stop or modify azacitidine treatment on your own; any changes must be guided by your haematology–oncology team. Generic Meds Mart exists to provide a discreet, reliable supply channel for Azadine 100 mg azacitidine injection, while all complex clinical decisions remain with your specialists.

FAQ about Azadine (Azacitidine)

Q1: What conditions is Azadine 100 mg used to treat?

Azadine 100 mg contains azacitidine, a hypomethylating agent used for myelodysplastic syndromes (MDS) and selected acute myeloid leukemia (AML) cases in adults, according to local prescribing information and specialist guidelines.

Q2: Is Azadine 100 mg an infusion or an injection under the skin?

Azadine 100 mg azacitidine can be given as a subcutaneous injection or as an intravenous infusion, depending on local protocols and patient factors. The powder in the vial is reconstituted by healthcare professionals, who then administer it using the route and schedule defined in your treatment plan.

Q3: How many treatment cycles of azacitidine will I need?

The number of azacitidine cycles varies between patients. Many people require multiple cycles, often at least six, before a full assessment of response is made, provided side effects remain manageable. Your haematology team will explain how many cycles they recommend and how they will evaluate benefit over time.

Q4: Will I need to stay in hospital for Azadine treatment?

Some patients receive Azadine 100 mg as day-care treatment, while others may need hospital admission, especially early in therapy or if complications arise. Decisions about inpatient versus outpatient management depend on your overall health, blood counts, infection risk and local practice.

Q5: Can Azadine 100 mg cure my disease?

In some patients, azacitidine can lead to durable remissions and significantly improved survival, but not everyone achieves a complete cure with hypomethylating therapy alone. For some individuals, Azadine 100 mg may serve as a bridge to other treatments such as stem cell transplantation. Your haematologist is best placed to discuss realistic goals of therapy in your specific situation.

Q6: Is Azadine 100 mg the same as Vidaza (Generic Vidaza)?
Azadine 100 mg is Generic Vidaza — it contains the same active ingredient (azacitidine) as Vidaza. It’s used for the same purpose at the same strength, while differences may be in manufacturer, inactive ingredients (excipients), vial appearance, and packaging. If you’re switching between products, confirm the substitution with a qualified healthcare professional.